Skip Navigation


Annals of Oncology Advance Access originally published online on September 9, 2007
Annals of Oncology 2007 18(11):1828-1833; doi:10.1093/annonc/mdm332
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
18/11/1828    most recent
mdm332v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Oudard, S.
Right arrow Articles by Andrieu, J.-M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Oudard, S.
Right arrow Articles by Andrieu, J.-M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2007 European Society for Medical Oncology

urogential tumors

Prostate-specific antigen doubling time before onset of chemotherapy as a predictor of survival for hormone-refractory prostate cancer patients

S. Oudard1, E. Banu1,*, F. Scotte1, A. Banu1, J. Medioni1, P. Beuzeboc2, F. Joly3, J.-M. Ferrero4, F. Goldwasser5 and J.-M. Andrieu1

1 Georges Pompidou European Hospital, Paris
2 Curie Institute, Paris
3 François Baclesse Centre, Caen
4 Antoine-Lacasagne Centre, Nice
5 Cochin Hospital, Paris, France

* Correspondence to: Dr S. Oudard, MD, Georges Pompidou European Hospital, Medical Oncology Department, 20 Leblanc Street, 75015 Paris, France. Tel: +33-1-56-09-34-34; Fax: +33-1-56-09-24-31; E-mail: stephane.oudard{at}egp.aphp.fr

Background: We evaluated the possible use of prostate-specific antigen doubling time (PSA-DT) before chemotherapy initiation as a surrogate marker of survival in hormone-refractory prostate cancer (HRPC) patients.

Patients and methods: Data from 250 consecutive metastatic HRPC patients treated with chemotherapy between February 2000 and November 2006 were retrospectively analysed. At least three PSA assays were required within 3 months before chemotherapy. PSA-DT was calculated as ln 2 divided by the slope of the log PSA line, and the difference between two log PSA levels was divided by the time interval. The primary endpoint was overall survival (OS). Survival rates according to PSA-DT were stratified on chemotherapy regimen. Multivariate Cox regression analysis was performed to isolate the impact of PSA-DT on OS, controlling for associate prognostic covariates.

Results: Patients received docetaxel- (82%) or mitoxantrone-based chemotherapy. The median PSA-DT was 45 days (range 4.7–1108 days). There were 174 deaths (70%). The median survival was 16.5 months (95% confidence interval [CI] = 12.5–20.5) and 26.4 months (95% CI = 20.3–32.4) for patients with a PSA-DT < 45 and ≥45 days, respectively. In the multivariate setting, the adjusted hazard ratio (HR) was 1.39 (95% CI = 1.03–1.89; P = 0.04), stratified by chemotherapy regimen.

Conclusion: A short PSA-DT before onset of chemotherapy in HRPC patients was associated with an increased risk of death. This could be useful as a stratification parameter in trials with new drugs in a metastatic setting.

Key words: chemotherapy, hormone-refractory prostate cancer, overall survival, predictive factor, prostate-specific antigen doubling time

Received for publication March 26, 2007. Revision received May 15, 2007. Accepted for publication May 21, 2007.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
G. Gravis, F. Bladou, N. Salem, A. Goncalves, B. Esterni, J. Walz, S. Bagattini, M. Marcy, S. Brunelle, and P. Viens
Results from a monocentric phase II trial of erlotinib in patients with metastatic prostate cancer
Ann. Onc., September 1, 2008; 19(9): 1624 - 1628.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.